OppenheimerFunds Inc. cut its position in AstraZeneca plc (NYSE:AZN) by 3.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 133,213 shares of the company’s stock after selling 5,157 shares during the period. OppenheimerFunds Inc.’s holdings in AstraZeneca were worth $4,622,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Valeo Financial Advisors LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at about $133,000. Calton & Associates Inc. acquired a new stake in shares of AstraZeneca in the 4th quarter valued at about $181,000. Wealthcare Advisory Partners LLC acquired a new stake in shares of AstraZeneca in the 3rd quarter valued at about $184,000. Neumann Capital Management LLC acquired a new stake in shares of AstraZeneca in the 4th quarter valued at about $202,000. Finally, Clean Yield Group acquired a new stake in shares of AstraZeneca in the 4th quarter valued at about $205,000. 15.13% of the stock is owned by hedge funds and other institutional investors.
Shares of AstraZeneca plc (NYSE AZN) opened at $33.79 on Friday. AstraZeneca plc has a 1 year low of $28.43 and a 1 year high of $36.70. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.62 and a current ratio of 0.80. The firm has a market capitalization of $85,561.23, a P/E ratio of 7.89, a price-to-earnings-growth ratio of 2.02 and a beta of 0.71.
The firm also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is currently 57.81%.
A number of analysts recently issued reports on the company. Zacks Investment Research cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 3rd. Leerink Swann increased their price objective on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 6th. BMO Capital Markets set a $40.00 price objective on AstraZeneca and gave the stock a “buy” rating in a research report on Tuesday, February 20th. Finally, JPMorgan Chase & Co. raised AstraZeneca from a “neutral” rating to an “overweight” rating in a research report on Friday, December 29th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company’s stock. AstraZeneca currently has a consensus rating of “Hold” and a consensus price target of $36.26.
WARNING: This article was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3253218/astrazeneca-plc-azn-shares-sold-by-oppenheimerfunds-inc.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.